News
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018
The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models
Deepak Lala, Tasir Haque, Hannah Feinman, Jianghong Wu, Yuren Wang, Amy Dwyer, Thu Truong, and Carol Lange
San Antonio Breast Cancer Symposium I Poster P6-20-13 I Dec 4-8, 2018